To provide solutions for saving and extending lives of people fighting cardiovascular disease, working and developing as an organic part of the health care system.
Main Goals of the Company:
- to market effective and safe medical devices;
- to meet the needs of cardiovascular surgeons;
- to comply with regulatory requirements for risk class 3 medical devices manufacturer;
- to improve existing products and create new products complying with the parameters of the equivalents on the market, considered to be the best based on the results of long-term observation;
- to introduce company's products into new markets;
- to increase welfare of the company and each of its employees.
Company's basic principles include:
- Designing new medical devices and improving the existing ones in cooperation with surgeons;
- Marketing effective and safe medical devices while maintaining optimal prices;
- Timely products delivery and meeting special shipment and storage requirements.
Company's products are used in clinics throughout Russia from Kaliningrad to Vladivostok.
According to the state contracts signed by cardiac surgery clinics in 2018, every third heart valve bioprosthesis purchased by Russian clinics was manufactured in NeoCor production lab.
NeoCor CJSC designes and manufactures implants applied in cardiovascular surgery from animal tissues under the license for medical devices manufacture No. FS-99-04-006051 dated November 13, 2018, issued by the Federal Service for Supervision in the Sphere of Health Care of the Russian Federation
The cardiovascular surgery biological prostheses production lab has been in business for more than 30 years and holds leading positions in this field. During this time, the company's employees have gained extensive experience in the sphere of cardiovascular implants design and production.
Since the 1970s, researchers lead by Russian Academy of Sciences member, Leonid Barbarash, have been designing biological substitutes for cardiovascular surgery in Kuzbass region. The very first heart valve replacement procedure with an in-house bioprosthesis was performed by Kuzbass cardiac surgeons in 1978.
In 1982, a specialized heart valves and blood vessels bioprostheses production lab was established in Kemerovo. It soon started supplying its products to Russian cardiac surgery clinics.
In 1990, the lab was turned into a structural unit of Kemerovo cardiology health centre. Research and development help the lab experts to design and start full-scale production not only of conventional biological valves, but also of completely new ones, treated with a substance belonging to a different chemical class. The new preservative prevented calcification of the prosthesis and expanded indications for procedures: the surgeons started treating younger patients.
In 1995, a biotechnological research and production department is established in Kemerovo cardiac health centre. It combines a bioprostheses production lab and a R&D test lab, dedicated to solving urgent cardiac surgery and cardiology problems. This tandem significantly reduces the time of new products and technologies introduction into production and clinical practice.
In 1999, the animal tissue preservation technology, developed in Kuzbass region, sparked great interest among foreign cardiac surgeons and was honoured with the prestigious Walton Lillehei award, who was a pioneer in open-heart surgery.
In 2002, the biological valve prostheses lab was transformed into CJSC "NeoCor".
In 2009, the Research Institute for Complex Issues of Cardiovascular Diseases, included into the Siberian Branch of Russian Academy of Sciences, was established as a spin-off from the R&D test lab.
Today, cooperation with Research Institute for Complex Issues of Cardiovascular Diseases, (Siberian Branch of Russian Academy of Sciences) empowers the company to develop innovative medical devices and improve marketed bioprostheses.
In 2003, company's quality management system “Design and manufacture of prostheses for cardiovascular surgery” was certified for compliance with ISO 9001:2008. The company was the first Russian medical devices manufacturer to successfully gain such certification.
In 2018, the company gained certification for its quality management system to ISO 13485:2016 “Medical Devices. Quality management systems. Requirements for regulatory purposes”.